Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04349969
Title Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Akeso
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.